三公大吃小棋牌游戏（www.eth108.vip）:Sanofi ends cancer drug trials
The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.三公大吃小棋牌游戏（www.eth108.vip）（三公开船）是用以太坊区块高度哈希值开奖的棋牌游戏，有别于传统三公大吃小棋牌游戏（三公开船）棋牌游戏，三公大吃小棋牌游戏（三公开船）游戏绝对公平，结果绝对无法预测。三公大吃小棋牌游戏（三公开船）由玩家PK，平台不参与。
PARIS: Sanofi is ending development of a key cancer medicine in a blow to the French drugmaker’s pipeline of experimental therapies.
The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.
The move leaves Sanofi even more dependent for growth on blockbuster Dupixent, an antibody treatment for ailments ranging from asthma to severe eczema.
The company’s slate of experimental medicines has faced other setbacks, including safety concerns regarding multiple sclerosis treatment tolebrutinib.,
Sanofi has included both amcenestrant and tolebrutinib as among six products in its pipeline that it prioritised as “potentially transformative” treatments.
Some investors are questioning the company’s growth trajectory after both of those medicines encountered problems.
UBS analysts last week downgraded Sanofi, saying there are few major catalysts coming soon to drive more excitement to the stock. — Bloomberg